From: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
Acute Migraine-Specific Medication Days
Baseline
N = 145 (100%)
Month 6
N = 113 (100%)
≥ 10
81 (55.9%)
27 (23.9%)
< 10
64 (44.1%)
86 (76.1%)